Oxaloplatine [French]

• Antineoplastic Agents
• ATC:L01XA03

• DACPLAT
• Eloxatin
• Oxalatoplatin
• Oxalatoplatinum
• Oxaliplatin [Usan:Inn:Ban]
• Oxaliplatino [Spanish]
• Oxaliplatinum [Latin]
• Oxaloplatine [French]
• Oxaloplatino [Spanish]

• No information avaliable

C₈H₁₂N₂O₄Pt

http://www.rxlist.com/cgi/generic/eloxatin.htm

Oxaloplatine_[French] FDA

Oxaloplatine_[French] MSDS

No information avaliable

395.27 g/mol

No information avaliable

No information avaliable

Solid

No information avaliable

No information avaliable

For the treatment of malignant neoplasm of colon, rectum, and ovary

Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

No information avaliable

No information avaliable

Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.

Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.

Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

Humans and other mammals